Quantcast

Industry news that matters to you.  Learn more

GENFIT and LabCorp Sign a Licensing Agreement to Expand Access to an Innovative Diagnostic Assay for Non-Alcoholic Steatohepatitis (NASH)

LabCorp, a leading global life sciences company, and GENFIT, a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, have announced the signing of a licensing agreement between GENFIT and Covance, LabCorp’s drug development business. The agreement will expand access to an innovative non-alcoholic steatohepatitis (NASH) liver diagnostic test for the clinical research market.

Profil Institute Unites Leading Experts in Biomarker Discovery and Clinical Research to Address the Medical Challenges of NAFLD/NASH

Profil Institute for Clinical Research, a clinical research organization (CRO) focused on diabetes, obesity and NAFLD/NASH, announced today a collaboration of experts in biomarker discovery and clinical research in the fields of metabolism, diabetes and obesity to address the medical challenges of NAFLD and NASH.